Cell differentiation in developing tissues is controlled by a small set of signaling pathways, which must coordinate the timing and levels of activation to ensure robust and precise outcomes. Highly coordinated activation of signaling pathways can result from cross-regulatory interactions in multi-pathway networks. Here we explore the dynamics and function of pathway coordination between the EGFR and DPP pathways during Drosophila wing-vein differentiation. We show that simultaneous activation of both the EGFR and DPP pathways must be maintained for vein cell differentiation and that above-threshold ectopic activation of either pathway is sufficient to drive vein cell differentiation outside the proveins. The joint activation of the EGFR and DPP signaling systems is ensured by a positive feedback loop, in which the two pathways stimulate each other at the level of ligand production.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710866PMC
http://dx.doi.org/10.1038/msb.2009.35DOI Listing

Publication Analysis

Top Keywords

egfr dpp
16
activation egfr
12
dpp pathways
12
cell differentiation
12
pathways drosophila
8
signaling pathways
8
vein cell
8
activation
6
pathways
6
differentiation
5

Similar Publications

Background: To investigate the safety and efficiency of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetic kidney disease.

Methods: We conducted a comprehensive literature search across multiple databases, including Embase, PubMed, CNKI, and the Cochrane Central Register of Controlled Trials, from inception to January 2024. The search focused on randomized controlled trials (RCTs) that directly compared DPP-4 inhibitors with placebos or other glucose-lowering therapies.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the kidney and heart health outcomes between two diabetes medications: DPP-4 inhibitors (DPP-4is) and SGLT-2 inhibitors (SGLT-2is) in patients with diabetic kidney disease (DKD).
  • Using Taiwan's health databases, researchers matched users of both medications and analyzed their effects on kidney and cardiovascular issues over two years.
  • Results showed that SGLT-2i users had significantly better outcomes, including lower risks of kidney failure and cardiovascular events, suggesting DPP-4is should be used less frequently in favor of SGLT-2is for adults with DKD.
View Article and Find Full Text PDF

Aim: To evaluate the renal prognosis of dipeptidyl peptidase-4 inhibitor (DPP-4i) users and non-users using real-world Asian data.

Methods: Using databases from DeSC Healthcare, Inc., patients aged 30 years or older who used antidiabetic drugs from 2014 to 2021 were identified.

View Article and Find Full Text PDF

Background/aim: Vildagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors that have been shown to improve hyperglycemia in clinical trials among patients with type 2 diabetes. However, few studies have examined the efficacy of vildagliptin in patients with diabetic kidney disease (DKD).

Patients And Methods: Eight patients with DKD received oral vildagliptin 50-100 mg/day.

View Article and Find Full Text PDF

Aims: About 20-40% patients with type 2 diabetes mellitus (T2DM) had an increased risk of developing diabetic nephropathy (DN). Dipeptidyl peptidase-4 inhibitors (DPP-4i) were recommended for treatment of T2DM, while the impact of DPP-4i on renal function remained unclear. This study aimed to explore the effect of DPP-4i on renal parameter of estimated glomerular filtration rate (eGFR) and albumin-to-creatinine ratio (ACR) in T2DM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!